FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2917389639> ?p ?o ?g. }

• W2917389639 endingPage "3500" @default.
• W2917389639 startingPage "3500" @default.
• W2917389639 abstract "Abstract Patients with AML have heterogeneous features, including those specific to the patient as well as those specific to the disease, such as leukemic burden and dynamic sub-clonal populations. Outside of clinical trials, few of these components are used to determine treatment. In order to move towards precision medicine, we have developed πiChemo, a computational application based on a dynamic mathematical modelling framework, using patient-, leukemia- and treatment-specific data to predict outcomes and optimize chemotherapy regimens for patients with AML. The model consists of a pharmacokinetic and pharmacodynamic (PK/PD) module that calculates the concentration and effect of Cytarabine Arabinoside (Ara-C) and Daunorubicin (DNR) in bone marrow (BM); and a population balance models (PBMs) module that describes normal populations (stem cells, progenitors, precursors) and abnormal populations (leukemic sensitive blasts (LSB) and leukemic resistant blasts (LRB)) in BM. The PBMs module also determines mature cell numbers in three lineages found in BM and peripheral blood (PB): (1) red blood cells (RBC), (2) white blood cells (WBC) and (3) lymphocytes (L). Model structure was analysed by global sensitivity analysis, which identified the most significant parameters on outcome predictions, re-estimated for each patient. The final integrated PK/PD & PBMs model has 1,295 differential equations, 8,044 algebraic equations, 9,335 variables, 25 fixed parameters and 4 degrees of freedom or variables to be optimized (Ara-C dose, Ara-C injection duration, DNR dose and DNR injection duration). Model validation, predictions and optimizations were performed using anonymised retrospective data from 28 patients with AML. The model required: (i) patient features: height, weight, age and gender, (ii) patient status: initial BM differential and PB cell counts, (iii) leukemia data: cellularity, presence of dysplasia and initial blast percentage and, (iv) treatment data: type (low-dose (LD) or intensive (DA)), dose, administration route (SC vs IV), administration mode (bolus injection vs infusion), time between injections and between cycles. The model predicted the absolute numbers of stem cells, progenitors, precursors, WBC, RBC, L, LSB and LRB in BM, and WBC, RBC, L and neutrophil count in PB during treatment for all patients. Model simulations predicted outcomes for 18 patients who achieved complete remission (7 LD & 11 DA), 4 patients who entered partial remission (2 LD & 2 DA) and 6 patients who relapsed (2 LD & 4 DA). The most remarkable results are those of prediction for BM blast percentage after each chemotherapy cycle and the PB neutrophil count for all patients. The notable fit between model predictions and daily patient data demonstrate model robustness and accuracy in the capacity to track patient-specific restaging BM and daily PB count evolution before, during and after treatment. The same patient datasets were used to apply an optimization algorithm that could maximize normal cell number and reduce leukemia burden, to personalize chemotherapy dose and administration for best outcomes. The results show that doses and administration methods vary between patients and between chemotherapy cycles for the same patient, depending on the evolution of normal and abnormal populations in BM. Low-dose continuous Ara-C infusions were more effective than rapid bolus injections, due to reduced chemotherapy effects on normal cells and subsequent quicker recovery in the normal BM compartments. RBC progenitors and precursors recovered faster than WBC and L lineages, and the recovery of normal BM cells was faster than that of normal mature cells in PB. The πiChemo tool requires only patient- and leukemia-specific initial conditions at diagnosis, easily obtained in standard clinical practice, for outcome predictions and treatment optimizations. Real-time model-fit testing and comparison of model results against daily PB cell counts would enable the re-estimation of significant parameters, increasing model accuracy and treatment effectiveness whilst therapy is ongoing. The πiChemo precision therapy tool has the potential to personalize optimal standard and novel treatments for AML in real-time. Disclosures No relevant conflicts of interest to declare." @default.
• W2917389639 created "2019-03-02" @default.
• W2917389639 creator A5022800515 @default.
• W2917389639 creator A5030892989 @default.
• W2917389639 creator A5031561153 @default.
• W2917389639 creator A5042492602 @default.
• W2917389639 creator A5048473531 @default.
• W2917389639 creator A5062286648 @default.
• W2917389639 creator A5067216819 @default.
• W2917389639 date "2018-11-29" @default.
• W2917389639 modified "2023-09-29" @default.
• W2917389639 title "Personalized and Optimized Low-Dose and Intensive Chemotherapy Treatments for Patients with Acute Myeloid Leukemia (AML)" @default.
• W2917389639 doi "https://doi.org/10.1182/blood-2018-99-119258" @default.
• W2917389639 hasPublicationYear "2018" @default.
• W2917389639 type Work @default.
• W2917389639 sameAs 2917389639 @default.
• W2917389639 citedByCount "1" @default.
• W2917389639 countsByYear W29173896392021 @default.
• W2917389639 crossrefType "journal-article" @default.
• W2917389639 hasAuthorship W2917389639A5022800515 @default.
• W2917389639 hasAuthorship W2917389639A5030892989 @default.
• W2917389639 hasAuthorship W2917389639A5031561153 @default.
• W2917389639 hasAuthorship W2917389639A5042492602 @default.
• W2917389639 hasAuthorship W2917389639A5048473531 @default.
• W2917389639 hasAuthorship W2917389639A5062286648 @default.
• W2917389639 hasAuthorship W2917389639A5067216819 @default.
• W2917389639 hasBestOaLocation W29173896391 @default.
• W2917389639 hasConcept C126322002 @default.
• W2917389639 hasConcept C143998085 @default.
• W2917389639 hasConcept C203014093 @default.
• W2917389639 hasConcept C2776694085 @default.
• W2917389639 hasConcept C2778041864 @default.
• W2917389639 hasConcept C2778461978 @default.
• W2917389639 hasConcept C2778729363 @default.
• W2917389639 hasConcept C2780007613 @default.
• W2917389639 hasConcept C2781021840 @default.
• W2917389639 hasConcept C2908647359 @default.
• W2917389639 hasConcept C71924100 @default.
• W2917389639 hasConcept C99454951 @default.
• W2917389639 hasConceptScore W2917389639C126322002 @default.
• W2917389639 hasConceptScore W2917389639C143998085 @default.
• W2917389639 hasConceptScore W2917389639C203014093 @default.
• W2917389639 hasConceptScore W2917389639C2776694085 @default.
• W2917389639 hasConceptScore W2917389639C2778041864 @default.
• W2917389639 hasConceptScore W2917389639C2778461978 @default.
• W2917389639 hasConceptScore W2917389639C2778729363 @default.
• W2917389639 hasConceptScore W2917389639C2780007613 @default.
• W2917389639 hasConceptScore W2917389639C2781021840 @default.
• W2917389639 hasConceptScore W2917389639C2908647359 @default.
• W2917389639 hasConceptScore W2917389639C71924100 @default.
• W2917389639 hasConceptScore W2917389639C99454951 @default.
• W2917389639 hasIssue "Supplement 1" @default.
• W2917389639 hasLocation W29173896391 @default.
• W2917389639 hasOpenAccess W2917389639 @default.
• W2917389639 hasPrimaryLocation W29173896391 @default.
• W2917389639 hasRelatedWork W2029347230 @default.
• W2917389639 hasRelatedWork W2060212395 @default.
• W2917389639 hasRelatedWork W2271311441 @default.
• W2917389639 hasRelatedWork W2382885598 @default.
• W2917389639 hasRelatedWork W2406230970 @default.
• W2917389639 hasRelatedWork W2414858770 @default.
• W2917389639 hasRelatedWork W2490958314 @default.
• W2917389639 hasRelatedWork W4313390310 @default.
• W2917389639 hasRelatedWork W812818912 @default.
• W2917389639 hasRelatedWork W2518313993 @default.
• W2917389639 hasVolume "132" @default.
• W2917389639 isParatext "false" @default.
• W2917389639 isRetracted "false" @default.
• W2917389639 magId "2917389639" @default.
• W2917389639 workType "article" @default.